I think this would be more of an issue if LL only worked in the cure of HIV. Someone could definitely buy us and shelve LL if that were the case. Buying CYDY though, while it may mean losing some of your HIV revenue, will also potentially gain you revenues in multiple types of cancer, in MASH, in inflammation, in Alzheimer's, in multiple types of fibrosis, etc. The revenues to be gained seem to far outweigh the revenues you would lose in HIV. Also, you get the added benefit of wiping out all of your competitors' revenues in HIV and those other indications.